Eisai Appoints New Trials Exec To Help Stop Late-Stage Failures
Eisai has tasked a new exec with making trials more likely to succeed just a few months after its candidate ovarian cancer blockbuster failed at Phase III.
Archives for April 15, 2013
Biotech Firm to Make Recombinant Proteins for Allergy Drug Developers
French biotech company ANGANY Genetics says its new platform can provide pharma companies low cost and high quality recombinant allergens for drug testing purposes.